drugset / Trial / NCT02080195
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
Phase 1/2
Terminated
1 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Maryland Stem Cell Research Fund · collab
NaSingle-groupOpen-labelTreatment
Summary
The main goal of the study is to determine if bone marrow transplant (BMT) from a less specific pool of donors in combination with high dose cyclophosphamide can induce remission of refractory systemic lupus erythematosus.
Timeline
- Start
- 2016-09-13
- Primary completion
- 2017-03-28
- Completion
- 2017-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |
| Background | Mycophenolate Mofetil | Small molecule | 15 mg/kg | — |
| Background | Tacrolimus | Small molecule | — | — |
| Background | Thymoglobulin | Protein / enzyme biologic | 2 mg/kg | — |